Puma Biotechnology, Inc.

NasdaqGS:PBYI 株式レポート

時価総額:US$157.6m

Puma Biotechnology 過去の業績

過去 基準チェック /56

Puma Biotechnologyは、平均年間62.7%の収益成長を遂げていますが、 Biotechs業界の収益は、年間 成長しています。収益は、平均年間19.3% 2.7%収益成長率で 減少しています。 Puma Biotechnologyの自己資本利益率は32.7%であり、純利益率は9.5%です。

主要情報

62.7%

収益成長率

63.1%

EPS成長率

Biotechs 業界の成長17.0%
収益成長率-2.7%
株主資本利益率32.7%
ネット・マージン9.5%
前回の決算情報30 Sep 2024

最近の業績更新

Puma Biotechnology's (NASDAQ:PBYI) Performance Is Even Better Than Its Earnings Suggest

Nov 14
Puma Biotechnology's (NASDAQ:PBYI) Performance Is Even Better Than Its Earnings Suggest

We Like The Quality Of Puma Biotechnology's (NASDAQ:PBYI) Earnings

May 09
We Like The Quality Of Puma Biotechnology's (NASDAQ:PBYI) Earnings

Recent updates

Puma Biotechnology's (NASDAQ:PBYI) Performance Is Even Better Than Its Earnings Suggest

Nov 14
Puma Biotechnology's (NASDAQ:PBYI) Performance Is Even Better Than Its Earnings Suggest

Is Puma Biotechnology (NASDAQ:PBYI) A Risky Investment?

Sep 07
Is Puma Biotechnology (NASDAQ:PBYI) A Risky Investment?

Lacklustre Performance Is Driving Puma Biotechnology, Inc.'s (NASDAQ:PBYI) 26% Price Drop

Aug 15
Lacklustre Performance Is Driving Puma Biotechnology, Inc.'s (NASDAQ:PBYI) 26% Price Drop

The Market Doesn't Like What It Sees From Puma Biotechnology, Inc.'s (NASDAQ:PBYI) Earnings Yet As Shares Tumble 25%

Jun 07
The Market Doesn't Like What It Sees From Puma Biotechnology, Inc.'s (NASDAQ:PBYI) Earnings Yet As Shares Tumble 25%

Here's Why We Think Puma Biotechnology (NASDAQ:PBYI) Might Deserve Your Attention Today

Jun 05
Here's Why We Think Puma Biotechnology (NASDAQ:PBYI) Might Deserve Your Attention Today

We Like The Quality Of Puma Biotechnology's (NASDAQ:PBYI) Earnings

May 09
We Like The Quality Of Puma Biotechnology's (NASDAQ:PBYI) Earnings

Puma Biotechnology: A Story In Flux Heading Into Mid-2024

May 05

Is There An Opportunity With Puma Biotechnology, Inc.'s (NASDAQ:PBYI) 46% Undervaluation?

Apr 10
Is There An Opportunity With Puma Biotechnology, Inc.'s (NASDAQ:PBYI) 46% Undervaluation?

There's Reason For Concern Over Puma Biotechnology, Inc.'s (NASDAQ:PBYI) Massive 31% Price Jump

Mar 01
There's Reason For Concern Over Puma Biotechnology, Inc.'s (NASDAQ:PBYI) Massive 31% Price Jump

Here's Why Puma Biotechnology (NASDAQ:PBYI) Has A Meaningful Debt Burden

Dec 27
Here's Why Puma Biotechnology (NASDAQ:PBYI) Has A Meaningful Debt Burden

Puma Biotechnology (NASDAQ:PBYI) Has A Somewhat Strained Balance Sheet

Sep 08
Puma Biotechnology (NASDAQ:PBYI) Has A Somewhat Strained Balance Sheet

Puma Biotechnology, Inc. (NASDAQ:PBYI) Held Back By Insufficient Growth Even After Shares Climb 34%

Apr 17
Puma Biotechnology, Inc. (NASDAQ:PBYI) Held Back By Insufficient Growth Even After Shares Climb 34%

We Think Puma Biotechnology (NASDAQ:PBYI) Can Stay On Top Of Its Debt

Dec 14
We Think Puma Biotechnology (NASDAQ:PBYI) Can Stay On Top Of Its Debt

Puma Biotechnology, Takeda enter licensing agreement for cancer treatment alisertib

Sep 20

Puma Biotechnology (NASDAQ:PBYI) Takes On Some Risk With Its Use Of Debt

Sep 05
Puma Biotechnology (NASDAQ:PBYI) Takes On Some Risk With Its Use Of Debt

Puma Biotechnology Non-GAAP EPS of $0.28, revenue of $59.5M

Aug 04

収支内訳

Puma Biotechnology の稼ぎ方とお金の使い方。LTMベースの直近の報告された収益に基づく。


収益と収入の歴史

NasdaqGS:PBYI 収益、費用、利益 ( )USD Millions
日付収益収益G+A経費研究開発費
30 Sep 24244238353
30 Jun 2421998952
31 Mar 24227158951
31 Dec 23236228950
30 Sep 2322949751
30 Jun 23230-29851
31 Mar 2323559450
31 Dec 2222809252
30 Sep 22218108753
30 Jun 22207-349060
31 Mar 22201-4910867
31 Dec 21253-2911672
30 Sep 21250-4812282
30 Jun 21255-3512686
31 Mar 21272-2711692
31 Dec 20225-6011898
30 Sep 20235-56120104
30 Jun 20241-42122110
31 Mar 20224-82126123
31 Dec 19272-76140133
30 Sep 19280-95151141
30 Jun 19287-92148147
31 Mar 19284-99155154
31 Dec 18251-114146165
30 Sep 18202-147136177
30 Jun 18145-210140190
31 Mar 1894-243125200
31 Dec 1728-292107208
30 Sep 176-30192214
30 Jun 170-28974216
31 Mar 170-27861217
31 Dec 160-27654223
30 Sep 160-26547219
30 Jun 160-26042219
31 Mar 160-25835224
31 Dec 150-23932208
30 Sep 150-22530196
30 Jun 150-20025176
31 Mar 150-17524151
31 Dec 140-14219123
30 Sep 140-1101496
30 Jun 140-891376
31 Mar 140-631152

質の高い収益: PBYIは 高品質の収益 を持っています。

利益率の向上: PBYIの現在の純利益率 (9.5%)は、昨年(1.6%)よりも高くなっています。


フリー・キャッシュフローと収益の比較


過去の収益成長分析

収益動向: PBYI過去 5 年間で収益を上げており、収益は年間62.7%増加しています。

成長の加速: PBYIの過去 1 年間の収益成長率 ( 525.3% ) は、5 年間の平均 ( 年間62.7%を上回っています。

収益対業界: PBYIの過去 1 年間の収益成長率 ( 525.3% ) はBiotechs業界16.6%を上回りました。


株主資本利益率

高いROE: PBYIの 自己資本利益率 ( 32.69% ) は 高い ですが、この指標は負債レベルが高いために歪んでいます。


総資産利益率


使用総資本利益率


過去の好業績企業の発掘